add_home_eng

Stem cells from the umbilical cord offer potential to replace destroyed tissue or damaged bodily functions, and hence to cure disease. 24 serious diseases are already treated using stem cells from people's own umbilical cord blood[1], and this number is rising rapidly. At present, more than 3300 clinical trials involving stem cells in general are in progress at university hospitals globally[2], and new results are published every month.

The stem cells extracted from the umbilical cord blood of newborns are the most 'potent' of the stem cells used for treatment as these are 'young' and can be collected very easily with no risk or inconvenience, while extracting stem cells from bone marrow requires surgical intervention.

This is why collecting umbilical cord blood from newborns offers a unique opportunity for parents-to-be, future generations and any highly developed welfare society which exploits institutional care to promote the health and wellbeing of its citizens.

1 parentsguidecordblood.org
2 clinicaltrials.gov

STEMCARE

StemCare A/S is the largest private stem cell bank in the Nordic region, specialising in the collection and freezing of stem cells from umbilical cord blood. The company was established in 2002 around the concept of making it possible for Danish citizens to retain the stem cells from the umbilical cords of their newborn babies for treatment of disease later on in life. There is major international trust in Denmark in this field, and at present StemCare stores stem cells from citizens of other countries in Europe as well.

logo_for_front
Annette

StemCare has been awarded EU funding for the StemXpand project